BRIEF published on 09/26/2025 at 14:50, 5 months 26 days ago EnVVeno Medical Engages in Virtual Investor Segment Amid FDA Appeal Medical Devices EnVVeno Medical VenoValve Chronic Venous Insufficiency FDA Appeal
PRESS RELEASE published on 09/26/2025 at 14:45, 5 months 26 days ago enVVeno Medical (NASDAQ:NVNO) Participates in Virtual Investor "What This Means" Segment enVVeno Medical Corporation announces CEO Robert Berman's participation in a Virtual Investor segment discussing the supervisory appeal for VenoValve® with FDA FDA EnVVeno Medical VenoValve Virtual Investor Supervisory Appeal
BRIEF published on 09/15/2025 at 14:50, 6 months 7 days ago EnVVeno Medical dépose un recours auprès de la FDA EnVVeno Medical Insuffisance Veineuse Chronique Valve VenoValve Appel Auprès De La FDA Processus Réglementaire
BRIEF published on 09/15/2025 at 14:50, 6 months 7 days ago EnVVeno Medical Pursues FDA Supervisory Appeal EnVVeno Medical VenoValve Chronic Venous Insufficiency Regulatory Process FDA Appeal
PRESS RELEASE published on 09/15/2025 at 14:45, 6 months 7 days ago enVVeno Medical Updates Regulatory Status of VenoValve(R) enVVeno Medical Corporation to file supervisory appeal with FDA regarding not-approvable letter for VenoValve® submission to treat deep venous CVI, aiming to bring innovative solution to patients FDA EnVVeno Medical Corporation VenoValve® Deep Venous Disease Supervisory Appeal
BRIEF published on 08/20/2025 at 13:05, 7 months 2 days ago EnVVeno Medical Receives Not-Approvable Letter from FDA for VenoValve EnVVeno Medical VenoValve FDA Decision Deep Venous Disease Premarket Approval
BRIEF published on 08/20/2025 at 13:05, 7 months 2 days ago EnVVeno Medical reçoit une lettre de non-approbation de la FDA pour VenoValve EnVVeno Medical Valve VenoValve Décision De La FDA Maladie Veineuse Profonde Approbation Préalable À La Mise Sur Le Marché
PRESS RELEASE published on 08/20/2025 at 13:00, 7 months 2 days ago enVVeno Receives Not-Approvable Letter from the FDA for the VenoValve(R) enVVeno Medical received a not-approvable letter from the FDA for VenoValve, citing lacking hemodynamic data and safety concerns. Company to work on new criteria and potential resubmission FDA Medical Device EnVVeno Medical VenoValve CVI
BRIEF published on 08/15/2025 at 15:26, 7 months 7 days ago EnVVeno Medical participera à la série de webinaires financiers Webull EnVVeno Medical Valve VenoValve Maladie Veineuse Profonde Webull Financial Biotechnologie/Technologie Médicale
BRIEF published on 08/15/2025 at 15:26, 7 months 7 days ago EnVVeno Medical to Present at Webull Financial Webinar Series EnVVeno Medical VenoValve Deep Venous Disease Webull Financial Biotech/MedTech
Published on 03/23/2026 at 08:00, 2 hours 15 minutes ago ABRIDGED, PRELIMINARY AND UNAUDITED QUARTERLY AND FULL YEAR RESULTS AND DETAILS OF MANAGEMENT CONFERENCE Call for the Fourth Quarter and Full Year Ended December 31, 2025 ("The Quarter" or "Q4 2025" and "FY 2025" Respectively)
Published on 03/23/2026 at 02:00, 8 hours 15 minutes ago FutureGen Industries Announces Open Market Investments
Published on 03/23/2026 at 09:19, 56 minutes ago Mister Spex Chooses Salesforce to further develop its Omnichannel Strategy
Published on 03/23/2026 at 09:00, 1 hour 15 minutes ago EQS Group launches Risk Management module to support continuous data and AI risk oversight
Published on 03/23/2026 at 08:10, 2 hours 5 minutes ago Entrée en négociations exclusives de cession de la participation dans Winncare
Published on 03/20/2026 at 19:00, 2 days 15 hours ago AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 days 15 hours ago AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 2 days 16 hours ago Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 2 days 16 hours ago Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA
